Dr Reddy, Nestle Health launch nutrition product for diabetes therapy users
This story was originally published at 21:22 IST on 7 May 2026
Register to read our real-time news.Informist, Thursday, May 7, 2026
NEW DELHI – Dr. Reddy's Laboratories Ltd. and Nestle Health Science Ltd. on Thursday launched 'Celevida GLP+'. It is a specialised nutrition product for people undergoing therapies of glucagon-like peptide-1, commonly known as GLP-1, and glucose-dependent insulinotropic polypeptide for type-II diabetes and obesity management in India. Nestle Health Science is a joint venture between Dr. Reddy's and Nestle India Ltd.
The product is for maintaining muscle mass and supporting nutritional intake during such therapies. Celevida GLP+ will be sold in a 350-gram pack through pharmacies, retail outlets, and e-commerce platforms. According to the companies, studies indicate that 25-40% of total weight loss from these therapies may come from lean body mass loss.
For the December quarter, Dr Reddy's had reported a consolidated net profit of INR 12.1 billion on consolidated revenues of INR 87.53 billion. Thursday, shares of the company ended at INR 1,307.60 on the National Stock Exchange, marginally lower compared to Wednesday. End
Reported by Gunjan Rajput
Edited by Avishek Dutta
For users of real-time market data terminals, Informist news is available exclusively on the NSE Cogencis WorkStation.
Cogencis news is now Informist news. This follows the acquisition of Cogencis Information Services Ltd. by NSE Data & Analytics Ltd., a 100% subsidiary of the National Stock Exchange of India Ltd. As a part of the transaction, the news department of Cogencis has been sold to Informist Media Pvt. Ltd.
Informist Media Tel +91 (11) 4220-1000
Send comments to feedback@informistmedia.com
© Informist Media Pvt. Ltd. 2026. All rights reserved.
To read more please subscribe
Share this Story:
